[SCHEDULE 13G/A] Akero Therapeutics, Inc. SEC Filing
Schedule 13G/A disclosure: Wellington Management Group LLP and related Wellington entities report beneficial ownership of 3,409,946 shares of Akero Therapeutics common stock, representing 4.28% of the class. The filing shows shared voting power of 2,924,691 shares and shared dispositive power of 3,409,946, with no sole voting or dispositive power. The securities are owned of record by clients of Wellington鈥檚 investment advisers rather than by Wellington itself.
The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, consistent with a passive, institutional ownership disclosure under Schedule 13G/A.
Dichiarazione Schedule 13G/A: Wellington Management Group LLP e soggetti collegati di Wellington riportano la titolarit脿 effettiva di 3.409.946 azioni ordinarie di Akero Therapeutics, pari al 4,28% della categoria. Il deposito indica potere di voto congiunto su 2.924.691 azioni e potere dispositivo congiunto su 3.409.946, senza potere di voto o dispositivo in via esclusiva. I titoli sono intestati ai clienti dei consulenti d'investimento di Wellington e non a Wellington stessa.
Il deposito include una certificazione che i titoli sono stati acquisiti e sono detenuti nell'ordinaria attivit脿 commerciale e non allo scopo di cambiare o influenzare il controllo dell'emittente, conforme a una comunicazione di partecipazione passiva istituzionale ai sensi dello Schedule 13G/A.
Divulgaci贸n Schedule 13G/A: Wellington Management Group LLP y entidades relacionadas informan la propiedad beneficiosa de 3.409.946 acciones ordinarias de Akero Therapeutics, que representan el 4,28% de la clase. La presentaci贸n muestra poder de voto compartido sobre 2.924.691 acciones y poder dispositivo compartido sobre 3.409.946, sin poder de voto o dispositivo exclusivo. Los valores est谩n registrados a nombre de clientes de los asesores de inversi贸n de Wellington y no de Wellington en s铆.
La presentaci贸n incluye una certificaci贸n de que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control del emisor, coherente con una divulgaci贸n de propiedad institucional pasiva seg煤n el Schedule 13G/A.
Schedule 13G/A 瓿奠嫓: 鞗半韯� 毵る媹歆�毹柬姼 攴鸽９ LLP 氚� 甏�霠� 鞗半韯� 瓿勳棿靷姅 鞎勳紑搿� 韰岆澕頁嫳鞀� 氤错喌欤� 3,409,946欤茧ゼ 靷嫟靸� 氤挫湢頃橁碃 鞛堨溂氅� 鞚措姅 頃措嫻 膦呺鞚� 4.28%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. 靹滊鞐愲姅 瓿惦彊 鞚橁舶甓� 2,924,691欤� 氚� 瓿惦彊 觳橂秳甓� 3,409,946欤�臧� 旮办灛霅橃柎 鞛堨溂氅� 雼弲 鞚橁舶甓岇澊雮� 雼弲 觳橂秳甓岇潃 鞐嗢潓鞙茧 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 歃濌秾鞚� 鞗半韯� 鞛愳泊臧� 鞎勲媽 鞗半韯挫潣 韴瀽 鞛愲靷� 瓿犼皾 氇呾潣搿� 氤挫湢霅橃柎 鞛堨姷雼堧嫟.
頃措嫻 鞝滌稖靹滊鞐愲姅 歃濌秾鞚� 鞓侅梾靸� 韱奠儊鞝侅澑 旆摑路氤挫湢 氇╈爜鞚措┌ 氚滍枆鞚胳潣 歆�氚瓣秾 氤�瓴届澊雮� 鞓來枼霠レ潉 頄夓偓頃橂牑電� 氇╈爜鞚� 鞎勲嫎鞚� 鞚胳頃橂姅 雮挫毄鞚� 韽暔霅橃柎 鞛堨溂氅�, 鞚措姅 Schedule 13G/A鞐� 霐半ジ 靾橂彊鞝� 旮瓣磤 氤挫湢 瓿奠嫓鞐� 攵�頃╉暕雼堧嫟.
Divulgation Schedule 13G/A : Wellington Management Group LLP et des entit茅s Wellington associ茅es d茅clarent la propri茅t茅 b茅n茅ficiaire de 3 409 946 actions ordinaires d'Akero Therapeutics, repr茅sentant 4,28% de la cat茅gorie. Le d茅p么t indique un pouvoir de vote partag茅 sur 2 924 691 actions et un pouvoir discr茅tionnaire partag茅 sur 3 409 946, sans pouvoir de vote ou discr茅tionnaire exclusif. Les titres sont d茅tenus au nom des clients des conseillers en investissement de Wellington et non par Wellington elle-m锚me.
Le d茅p么t comprend une certification selon laquelle les titres ont 茅t茅 acquis et sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le de l'茅metteur, conform茅ment 脿 une divulgation de participation institutionnelle passive en vertu du Schedule 13G/A.
Schedule 13G/A-Offenlegung: Wellington Management Group LLP und zugeh枚rige Wellington-Einheiten melden die wirtschaftliche Inhaberschaft von 3.409.946 Aktien der Stammaktien von Akero Therapeutics, was 4,28% der Klasse entspricht. Die Einreichung weist ein gemeinsames Stimmrecht 眉ber 2.924.691 Aktien und ein gemeinsames Verf眉gungsmacht 眉ber 3.409.946 Aktien aus, wobei kein alleiniges Stimm- oder Verf眉gungsrecht besteht. Die Wertpapiere sind im Namensbestand von Kunden der Anlageberater von Wellington und nicht von Wellington selbst gehalten.
Die Einreichung enth盲lt eine Best盲tigung, dass die Wertpapiere im gew枚hnlichen Gesch盲ftsverlauf erworben und gehalten werden und nicht mit dem Ziel, die Kontrolle 眉ber den Emittenten zu 盲ndern oder zu beeinflussen 鈥� entsprechend einer passiven institutionellen Beteiligungsmitteilung nach Schedule 13G/A.
- None.
- None.
Insights
TL;DR: Wellington reports a non-controlling institutional stake of 3.41M shares (4.28%), disclosed as held on behalf of clients.
The position size of 3,409,946 shares equates to 4.28% of Akero鈥檚 common stock as reported in the filing, below the 5% materiality threshold that typically triggers Schedule 13D scrutiny. The reporting shows shared voting power of 2,924,691 and shared dispositive power of 3,409,946, indicating control resides with client accounts rather than a single Wellington-controlled account. This is a routine, transparent disclosure by an investment adviser and holding-company group.
TL;DR: The filing documents passive, client-owned positions within Wellington鈥檚 adviser network and does not signal a control change.
Itemized cover-page data and Item 10 certification state the securities are held in the ordinary course of business and not for influencing control, which aligns with Schedule 13G/A usage. The filing also identifies the reporting persons as holding companies and investment-adviser entities and lists relevant subsidiaries and adviser affiliates. Because the stake is under 5% and voting/dispositive powers are shared, this disclosure is informational rather than governance-changing.
Dichiarazione Schedule 13G/A: Wellington Management Group LLP e soggetti collegati di Wellington riportano la titolarit脿 effettiva di 3.409.946 azioni ordinarie di Akero Therapeutics, pari al 4,28% della categoria. Il deposito indica potere di voto congiunto su 2.924.691 azioni e potere dispositivo congiunto su 3.409.946, senza potere di voto o dispositivo in via esclusiva. I titoli sono intestati ai clienti dei consulenti d'investimento di Wellington e non a Wellington stessa.
Il deposito include una certificazione che i titoli sono stati acquisiti e sono detenuti nell'ordinaria attivit脿 commerciale e non allo scopo di cambiare o influenzare il controllo dell'emittente, conforme a una comunicazione di partecipazione passiva istituzionale ai sensi dello Schedule 13G/A.
Divulgaci贸n Schedule 13G/A: Wellington Management Group LLP y entidades relacionadas informan la propiedad beneficiosa de 3.409.946 acciones ordinarias de Akero Therapeutics, que representan el 4,28% de la clase. La presentaci贸n muestra poder de voto compartido sobre 2.924.691 acciones y poder dispositivo compartido sobre 3.409.946, sin poder de voto o dispositivo exclusivo. Los valores est谩n registrados a nombre de clientes de los asesores de inversi贸n de Wellington y no de Wellington en s铆.
La presentaci贸n incluye una certificaci贸n de que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control del emisor, coherente con una divulgaci贸n de propiedad institucional pasiva seg煤n el Schedule 13G/A.
Schedule 13G/A 瓿奠嫓: 鞗半韯� 毵る媹歆�毹柬姼 攴鸽９ LLP 氚� 甏�霠� 鞗半韯� 瓿勳棿靷姅 鞎勳紑搿� 韰岆澕頁嫳鞀� 氤错喌欤� 3,409,946欤茧ゼ 靷嫟靸� 氤挫湢頃橁碃 鞛堨溂氅� 鞚措姅 頃措嫻 膦呺鞚� 4.28%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. 靹滊鞐愲姅 瓿惦彊 鞚橁舶甓� 2,924,691欤� 氚� 瓿惦彊 觳橂秳甓� 3,409,946欤�臧� 旮办灛霅橃柎 鞛堨溂氅� 雼弲 鞚橁舶甓岇澊雮� 雼弲 觳橂秳甓岇潃 鞐嗢潓鞙茧 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 歃濌秾鞚� 鞗半韯� 鞛愳泊臧� 鞎勲媽 鞗半韯挫潣 韴瀽 鞛愲靷� 瓿犼皾 氇呾潣搿� 氤挫湢霅橃柎 鞛堨姷雼堧嫟.
頃措嫻 鞝滌稖靹滊鞐愲姅 歃濌秾鞚� 鞓侅梾靸� 韱奠儊鞝侅澑 旆摑路氤挫湢 氇╈爜鞚措┌ 氚滍枆鞚胳潣 歆�氚瓣秾 氤�瓴届澊雮� 鞓來枼霠レ潉 頄夓偓頃橂牑電� 氇╈爜鞚� 鞎勲嫎鞚� 鞚胳頃橂姅 雮挫毄鞚� 韽暔霅橃柎 鞛堨溂氅�, 鞚措姅 Schedule 13G/A鞐� 霐半ジ 靾橂彊鞝� 旮瓣磤 氤挫湢 瓿奠嫓鞐� 攵�頃╉暕雼堧嫟.
Divulgation Schedule 13G/A : Wellington Management Group LLP et des entit茅s Wellington associ茅es d茅clarent la propri茅t茅 b茅n茅ficiaire de 3 409 946 actions ordinaires d'Akero Therapeutics, repr茅sentant 4,28% de la cat茅gorie. Le d茅p么t indique un pouvoir de vote partag茅 sur 2 924 691 actions et un pouvoir discr茅tionnaire partag茅 sur 3 409 946, sans pouvoir de vote ou discr茅tionnaire exclusif. Les titres sont d茅tenus au nom des clients des conseillers en investissement de Wellington et non par Wellington elle-m锚me.
Le d茅p么t comprend une certification selon laquelle les titres ont 茅t茅 acquis et sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le de l'茅metteur, conform茅ment 脿 une divulgation de participation institutionnelle passive en vertu du Schedule 13G/A.
Schedule 13G/A-Offenlegung: Wellington Management Group LLP und zugeh枚rige Wellington-Einheiten melden die wirtschaftliche Inhaberschaft von 3.409.946 Aktien der Stammaktien von Akero Therapeutics, was 4,28% der Klasse entspricht. Die Einreichung weist ein gemeinsames Stimmrecht 眉ber 2.924.691 Aktien und ein gemeinsames Verf眉gungsmacht 眉ber 3.409.946 Aktien aus, wobei kein alleiniges Stimm- oder Verf眉gungsrecht besteht. Die Wertpapiere sind im Namensbestand von Kunden der Anlageberater von Wellington und nicht von Wellington selbst gehalten.
Die Einreichung enth盲lt eine Best盲tigung, dass die Wertpapiere im gew枚hnlichen Gesch盲ftsverlauf erworben und gehalten werden und nicht mit dem Ziel, die Kontrolle 眉ber den Emittenten zu 盲ndern oder zu beeinflussen 鈥� entsprechend einer passiven institutionellen Beteiligungsmitteilung nach Schedule 13G/A.
FAQ
What stake does Wellington report in Akero Therapeutics (AKRO)?
How much voting power does Wellington share for AKRO?
Does Wellington have sole dispositive power over the AKRO shares?
Are the AKRO shares held by Wellington or its clients?
What type of SEC filing was submitted for AKRO?
